Immunomodulatory drugs Revlimid super( registered ) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

• Published in: Cancer Immunology, Immunotherapy Vol. 57; no. 12; pp. 1849 - 1859
• Main Authors: Zhu, Dan, Corral, Laura G, Fleming, Yuedi W, Stein, Bernd
• Format: Journal Article
• Language: English
• Published: 01.12.2008
• DOI: 10.1007/s00262-008-0512-7
• ISSN: 0340-7004

Revlimid super( registered ) (Lenalidomide, CC-5013) and CC-4047 are IMiDs super( registered ) immunomodulatory drugs that have been described as having immunomodulatory properties and anti-tumor activity. Here we report proapoptotic effects of CC-5013 and CC-4047 on tumor cells in a co-culture model of PBMC and tumor cells. CC-5013 and CC-4047 enhanced PBMC activity leading to tumor cell apoptosis in K562/PBMC co-culture model. We also demonstrate that the natural killer (NK) cell population of PBMC was essential in inducing K562 apoptosis. Increases of NK and natural killer T (NKT) cell populations by CC-5013 and CC-4047 was observed along with modulation of NK cell CD56 adhesion marker. In addition, our data indicate that NK activation by CC-4047 was dependent on other cell types of PBMC. We expanded the application of K562/PBMC co-culture model to other hematological and solid tumors. In Raji/PBMC co-culture model, CC-5013 and CC-4047 dose-dependently augmented tumor cell apoptosis. Pre-treatment of Raji cells with Rituximab further enhanced apoptosis induced by CC-5013 or CC-4047-treated PBMC. Moreover, CC-5013 and CC-4047 significantly increased PC-3 prostate cancer cell apoptosis in PC-3/PBMC co-culture, either as single agent or in combination with Docetaxel. Together, the results reveal that co-culture models are suitable cellular systems to assess anti-tumor activities of these compounds. Our findings support clinical evaluation of CC-5013 and CC-4047 in relapsed NHL with Rituximab and in prostate cancer with Docetaxel.